Guardant Health (GH)

• Market cap: $3.79B
• 1 day: 5.94%
• 5 days: 3.93%
• 1 month: 47.22%
• 3 months: 8.10%
• 6 months: 23.86%
• Year to date: 15.73%
• 1 year: 28.37%
• 5 years: -60.85%
• 10 years: -4.72%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Employees: 1,779

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

29% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 73

5.52% more ownership

Funds ownership: 97.04% [Q2] → 102.56% (+5.52%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

6% less funds holding

Funds holding: 279 [Q2] → 262 (-17) [Q3]

16% less capital invested

Capital invested by funds: $3.35B [Q2] → $2.83B (-$520M) [Q3]

28% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 60

62% less call options, than puts

Call options by funds: $21.3M | Put options by funds: $56M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 14% upside
• Avg. target: $42 38% upside
• High target: $50 63% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Julia Qin 25% 1-year accuracy 1 / 4 met price target	63% upside $50	Overweight Maintained	7 Nov 2024
Goldman Sachs Matthew Sykes 43% 1-year accuracy 12 / 28 met price target	17% upside $36	Buy Maintained	7 Nov 2024
Bernstein Eve Burstein 0% 1-year accuracy 0 / 1 met price target	14% upside $35	Outperform Maintained	30 Oct 2024
Leerink Partners	63% upside $50	Outperform Maintained	17 Oct 2024
UBS Dan Leonard 44% 1-year accuracy 4 / 9 met price target	30% upside $40	Buy Maintained	21 Aug 2024